PAPPA抗体;PAPPA Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P12019(PAPPA Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

Pregnancy-associated plasma protein-A (PAPP-A) is a metalloproteinase first identified in the 1970s as a high-molecular-weight glycoprotein abundantly present in the serum of pregnant individuals. It belongs to the metzincin superfamily and plays a critical role in regulating insulin-like growth factor (IGF) signaling by cleaving insulin-like growth factor-binding proteins (IGFBPs), particularly IGFBP-4. thereby releasing bioactive IGF to promote cell growth and tissue repair. Beyond pregnancy, PAPP-A is implicated in cardiovascular diseases, cancer, and aging-related conditions due to its involvement in extracellular matrix remodeling and cellular proliferation.

PAPP-A antibodies are essential tools for both research and clinical diagnostics. In prenatal screening, anti-PAPP-A antibodies are used in first-trimester combined tests to measure maternal serum PAPP-A levels, as low concentrations correlate with an increased risk of chromosomal abnormalities like Down syndrome. In cardiovascular research, these antibodies help detect PAPP-A overexpression in unstable atherosclerotic plaques, linked to acute coronary events. Additionally, PAPP-A antibodies aid in studying its oncogenic roles in cancers, where elevated PAPP-A expression may drive tumor progression.

Available as monoclonal or polyclonal variants, these antibodies are validated for techniques such as ELISA, immunohistochemistry, and Western blot. Challenges include ensuring specificity due to structural similarities with related proteases. Ongoing research focuses on therapeutic applications, including PAPP-A inhibition strategies for age-related diseases. Overall, PAPP-A antibodies remain pivotal in elucidating biological mechanisms and improving diagnostic accuracy across multiple medical fields.